Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes ...
Morning Overview on MSN
A Moderna mRNA flu shot won a unanimous FDA panel nod for older adults
Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026 ...
Asianet Newsable on MSN
mRNA stock rallies over 40% in June: Moderna bets its future on cancer, autoimmune disease and AI-powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
MarketBeat on MSN
Short Squeeze Alert-Moderna Stock Surges on New Strategy
Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...
Shares of Moderna (NASDAQ: MRNA) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it ...
The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...
Provides broad overview of Company's research and early development programs expected to continue to fuel future ...
In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transformative for ...
May 6 (Reuters) - Moderna's (MRNA.O), opens new tab mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results